CX3CR1 and neoplasm: These results show the response to PD-1 mAb + CX3CR1 immunotherapy is characterized by a remodeling of the myeloid compartments in the tumor with the combination treatment skewing the myeloid populations towards more mature macrophages and fewer MDSC.